What is Cytek Biosciences, Inc.'s revenue?

Cytek Biosciences, Inc. (CTKB) generated $204.2M in revenue over the trailing twelve months, up 3.6% year over year.

Is Cytek Biosciences, Inc. profitable?

Cytek Biosciences, Inc. is not currently profitable: it reported a net loss of $74.0M over the trailing twelve months, a -36.2% net margin.

What are Cytek Biosciences, Inc.'s profit margins?

Gross margin is 51.7% and operating margin is -21.5%, with a -36.2% net margin.

What is Cytek Biosciences, Inc.'s earnings per share?

Cytek Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.57.

Where does Cytek Biosciences, Inc.'s income statement data come from?

Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Cytek Biosciences, Inc. CTKB Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$204.17M+3.6%	$201.49M+0.5%	$196.83M-2.2%	$196.04M-0.8%	$197.05M-1.9%
Total cost of revenue	$98.61M+11.1%	$97.03M+8.6%	$91.6M+1.0%	$89.35M+0.4%	$88.8M-0.7%
Gross profit	$105.56M-2.5%	$104.46M-6.0%	$105.23M-4.8%	$106.68M-1.8%	$108.25M-2.8%
Gross margin	51.7%-3.2pp	51.8%-3.6pp	53.5%-1.5pp	54.4%-0.5pp	54.9%-0.5pp
Research and development	$36.35M-7.6%	$36.47M-7.4%	$37.23M-8.2%	$38.16M-8.8%	$39.33M-10.6%
Selling and marketing	$48.58M-1.0%	$49.44M+0.7%	$48.18M-1.3%	$48.95M+1.0%	$49.08M-2.9%
General and administrative	$64.51M+44.6%	$58.94M+36.7%	$51.62M+15.2%	$46.44M+5.0%	$44.6M+3.0%
Other operating expenses	$149.43M+12.3%	$144.85M+10.0%	$137.03M+2.1%	$133.54M-0.7%	$133.01M-3.5%
Total operating expenses	$149.43M+12.3%	$144.85M+10.0%	$137.03M+2.1%	$133.54M-0.7%	$133.01M-3.5%
Operating income	-$43.87M—	-$40.39M—	——	——	——
Operating margin	-21.5%—	-20%—	——	——	——
Interest expense	——	——	-$4.73M-535%	-$5.11M-427%	-$5.39M-393%
Interest income	$2.5M-41.6%	$2.22M-56.7%	$2.55M-54.9%	$3.41M-41.7%	$4.27M-24.2%
Other income (expense), net	$7.93M-52.8%	$10.54M-28.9%	$16.32M+39.1%	$19.3M+102%	$16.79M+56.1%
Income tax expense	$38.06M+1,060%	$36.7M+11,368%	-$2.67M-52.2%	-$1.16M-189%	$3.28M+179%
Net income	-$74M—	-$66.54M—	——	——	——
Net margin	-36.2%—	-33%—	——	——	——
Income from continuing operations	-$0.57—	-$0.51—	——	——	——
Diluted earnings per share	-$0.57—	-$0.51—	——	——	——
Basic earnings per share	-$0.57—	-$0.51—	——	——	——
Weighted-average shares, diluted	510.9M-2.3%	510.6M-2.9%	513.4M-3.2%	518.7M-2.8%	523.2M-2.8%
Weighted-average shares, basic	510.9M-2.0%	510.6M-2.6%	513.4M-2.9%	516.9M-3.2%	521.4M-3.1%
Continuing operations (in dollars per share)	-$0.57—	-$0.51—	——	——	——
Continuing operations (in dollars per share)	-$0.57—	-$0.51—	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$71.03M—	-$64.31M—	——	——	——
Foreign currency translation gains (losses)	$3.06M+234%	$2.17M+75.9%	$784K—	$144K—	$916K—
Other income, net (Note 6)	$5.88M-17.6%	$8.8M+97.2%	$9.04M+26.1%	$10.78M+104%	$7.13M+2.4%
Revenue From Contract With Customer Excluding Assessed Tax	$204.17M+3.6%	$201.49M+0.5%	$196.83M-2.2%	$196.04M-0.8%	$197.05M-1.9%
EBIT	-$43.87M—	-$40.39M—	——	——	——
EBITDA	-$36.3M—	-$32.81M—	——	——	——
EBITDA	-$36.3M—	-$32.81M—	——	——	——
EBITDA margin	-17.8%—	-16.3%—	——	——	——
EBIT	-$43.87M—	-$40.39M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Cytek Biosciences, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s revenue?: Cytek Biosciences, Inc. (CTKB) generated $204.2M in revenue over the trailing twelve months, up 3.6% year over year.
Is Cytek Biosciences, Inc. profitable?: Cytek Biosciences, Inc. is not currently profitable: it reported a net loss of $74.0M over the trailing twelve months, a -36.2% net margin.
What are Cytek Biosciences, Inc.'s profit margins?: Gross margin is 51.7% and operating margin is -21.5%, with a -36.2% net margin.
What is Cytek Biosciences, Inc.'s earnings per share?: Cytek Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.57.
Where does Cytek Biosciences, Inc.'s income statement data come from?: Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.